Literature DB >> 19250191

5alpha-reductase isozymes and androgen actions in the prostate.

Yuan-Shan Zhu1, Julianne L Imperato-McGinley.   

Abstract

Androgens acting via the androgen receptor play critical roles in prostate development, growth, and pathogenesis. There are two potent androgens, testosterone and dihydrotestosterone (DHT), in humans and mammals. DHT is converted from testosterone by 5alpha-reductase isozymes. Two 5alpha-reductase isozymes have been identified. Although both isozymes are expressed, 5alpha-reductase-2 is the predominant isozyme in the human prostate. Mutations in 5alpha-reductase-2 gene cause the 5alpha-reductase-2 deficiency syndrome. Affected 46, XY individuals have a small, nonpalpable, and rudimentary prostate in adulthood. Neither benign prostate hyperplasia (BPH) nor prostate cancer has been reported in these patients. The prostate is small in animals with 5alpha-reductase-2 gene knockout or treated with specific 5alpha-reductase inhibitors. 5alpha-reductase isozymes are molecular targets for the prevention and treatment of BPH and prostate cancer. Moreover, androgen actions on prostate gene expression and cell growth are directly modulated by estrogen receptor ligands via protein-protein interactions. The studies of 5alpha-reductases and androgen actions highlight the importance of 5alpha-reductase isozymes in male sexual differentiation and prostate physiology and pathophysiology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19250191     DOI: 10.1111/j.1749-6632.2009.04115.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  20 in total

1.  Impact of Formulation on the Pharmacokinetics of Dutasteride: Results from Two Phase I Studies.

Authors:  Michael Fossler; John Zhu; Claus Roehrborn; Paul McAleese; Michael Manyak
Journal:  Clin Drug Investig       Date:  2016-09       Impact factor: 2.859

Review 2.  [What comes after docetaxel?].

Authors:  C-H Ohlmann; M Stöckle
Journal:  Urologe A       Date:  2010-01       Impact factor: 0.639

Review 3.  [Third generation anti-androgen therapy of advanced prostate cancer].

Authors:  C-H Ohlmann; J Kamradt; M Stöckle
Journal:  Urologe A       Date:  2012-04       Impact factor: 0.639

Review 4.  The link between benign prostatic hyperplasia and prostate cancer.

Authors:  David D Ørsted; Stig E Bojesen
Journal:  Nat Rev Urol       Date:  2012-11-20       Impact factor: 14.432

5.  Influence of immune inflammation on androgen receptor expression in benign prostatic hyperplasia tissue.

Authors:  Zong-Lin Wu; Ya Yuan; He Geng; Shu-Jie Xia
Journal:  Asian J Androl       Date:  2011-12-12       Impact factor: 3.285

6.  Kinase modulation of androgen receptor signaling: implications for prostate cancer.

Authors:  Kalpit Shah; Neil A Bradbury
Journal:  Cancer Cell Microenviron       Date:  2015-11-19

Review 7.  Androgen regulation of prostate cancer: where are we now?

Authors:  G Corona; E Baldi; M Maggi
Journal:  J Endocrinol Invest       Date:  2011-02-04       Impact factor: 4.256

8.  Age and Obesity Promote Methylation and Suppression of 5α-Reductase 2: Implications for Personalized Therapy of Benign Prostatic Hyperplasia.

Authors:  Seth K Bechis; Alexander G Otsetov; Rongbin Ge; Zongwei Wang; Mark G Vangel; Chin-Lee Wu; Shahin Tabatabaei; Aria F Olumi
Journal:  J Urol       Date:  2015-04-25       Impact factor: 7.450

9.  Suppression of DHT-induced paracrine stimulation of endothelial cell growth by estrogens via prostate cancer cells.

Authors:  Juan Wen; Yuan Zhao; Jinghe Li; Chunyan Weng; Jingjing Cai; Kan Yang; Hong Yuan; Julianne Imperato-McGinley; Yuan-Shan Zhu
Journal:  Prostate       Date:  2013-02-19       Impact factor: 4.104

Review 10.  Minireview: Nuclear receptor-controlled steroid hormone synthesis and metabolism.

Authors:  Jinhan He; Qiuqiong Cheng; Wen Xie
Journal:  Mol Endocrinol       Date:  2009-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.